請輸入關鍵字:

熱門搜尋:

Boehringer-Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox

日期:2020年2月19日 上午9:50

Boehringer Ingelheim offers MyStudyWindow to provide patients, families, caregivers, and doctors consistent access to information about Boehringer Ingelheim’s actively recruiting studies conducted at global site locations
The platform features patient-centric study titles and descriptions, educational content, and guidance on the clinical trial selection and enrollment process
Anonymous condition-based questionnaires identify and pre-screen potentially relevant studies based on a few questions about patient diagnosis, disease stage, and treatment history

INGELHEIM, Germany & RALEIGH, N.C.--()--Boehringer Ingelheim and Carebox Healthcare Solutions announced the recent launch of MyStudyWindow (www.mystudywindow.com), a digital platform empowering patients, families, caregivers, and doctors to learn about Boehringer Ingelheim’s studies by offering information in an easy to access and understandable way. The collaboration brings together Carebox’ expertise in study matching based on patient eligibility criteria and Boehringer Ingelheim’s extensive scientific capabilities to pursue innovation on behalf of patients around the world.

Mohammed Ali, Global Head of Digital Development, Global Clinical Operations at Boehringer Ingelheim, says: “This initial release of MyStudyWindow represents an important step towards our vision to bring patients and physicians closer to the clinical trials environment. We plan to establish a next-generation platform empowering patients who consider to participate in or to learn about Boehringer Ingelheim studies and research. In addition, we aim to support doctors to find the information they need to consult on and pursue a well-informed treatment.”

The digital platform MyStudyWindow follows a patient-centric approach using lay friendly language, educational content and user-friendly features that provide guidance: Users can select from a range of condition-specific questionnaires to anonymously answer questions about a patient’s diagnosis, disease stage, and treatment history. MyStudyWindow instantly matches the user to potentially relevant clinical studies from the Boehringer Ingelheim portfolio, suggests nearby study site locations, and provides guidance on contacting the site for next steps. For studies that Boehringer Ingelheim would conduct in the future, patients will have the opportunity to provide feedback on their research experience to further stepping closer towards clinical trial democratization. The functions are facilitated by artificial intelligence powered automation which enables Carebox to continuously curate and structure eligibility criteria for Boehringer Ingelheim clinical trials.

“We are proud to be part of this project as the technology partner to develop and operate MyStudyWindow as a cloud-based SaaS solution”, explains Brian Weiss, CEO of Carebox Healthcare Solutions. “We are looking forward to continuing to expand the functionality and global reach of MyStudyWindow to further Boehringer Ingelheim’s commitment to patient-centric clinical research designs.”

Increasing patient and doctor awareness of clinical study opportunities and improving access is an industry challenge. Often times a lack of awareness leads to potential issues for up to 75 percent of investigators who fail to enroll the target number of participants. Furthermore, this impediment leads to as much as 90 percent of all clinical trials worldwide failing to enroll patients within the target amount of time and must extend their enrollment period.1 The parties involved in healthcare innovation increasingly recognize the role of patients and caregivers as key stakeholders in clinical research. Boehringer Ingelheim believes that the empowerment of patients and caregivers can be beneficial for study recruitment and help them to go into an informed dialog, especially those living with rare diseases.

Please click on the following link for ‘Notes to Editors’ and ‘References’:

http://www.boehringer-ingelheim.com/press-release/mystudywindow

Boehringer-Ingelheim Launches Patient-Centric MyStudyWindow Powered by Carebox

Contacts

Media Contacts:
Boehringer Ingelheim
Sarah Soetbeer
Boehringer Ingelheim Corporate Center GmbH
Communications + Public Affairs
P: +49 6132 77-183874
sarah.soetbeer@boehringer-ingelheim.com

Carebox Healthcare Solutions
Brian Weiss
Carebox Healthcare Solutions, Inc.
brian.weiss@careboxhealth.com

Collaboration Requests:
Boehringer Ingelheim
Sonia Houston Pichardo
Business Lead for MyStudyWindow
sonia.houston_pichardo@boehringer-Ingelheim.com

財華網所刊載內容之知識產權為財華網及相關權利人專屬所有或持有。未經許可,禁止進行轉載、摘編、複製及建立鏡像等任何使用。

如有意願轉載,請發郵件至content@finet.com.hk,獲得書面確認及授權後,方可轉載。

下載財華財經APP,把握投資先機
https://www.finet.com.cn/app

更多精彩内容,請點擊:
財華網(https://www.finet.hk/)
財華智庫網(https://www.finet.com.cn)
現代電視FINTV(https://www.fintv.hk)

相關文章

2月18日
杜拜電力供應的每年客戶分鐘損失(CML)為1.86分鐘
2月18日
Leman Micro Devices:智能手機能檢出感染症狀,讓人人都能在掌中監測健康
2月18日
玫琳凱公司宣佈女演員、慈善家Monique Coleman成為首位「粉紅改變生活」獎得主
2月18日
關於瀨戶內海的“DEEP JAPAN”展覽已在關西國際機場揭幕
2月18日
B2Broker推出B2Core,為企業提供套裝式的全新交易室概念
2月18日
歐睿國際2020全球消費者趨勢
2月18日
2月17日
NIPPON Platform和韓亞銀行主導的Global Loyalty Network (GLN)宣佈策略性業務合作
2月17日
玫琳凱參加2020年Generational Dermatology Palm春季研討會
2月17日
Octapharma Group 2019年銷售收入與營業淨利均強勁成長

視頻

快訊

13:30
【異動股】能源金屬板塊下挫,盛新锂能(002240.CN)跌4.57%
13:28
廣州:支持人工智能、虛擬現實、元宇宙、超高清視頻等技術和游戲電競產業深度融合
13:24
《廣州市扶持游戲電競產業發展的十八條措施》發佈
13:15
【異動股】锂礦概念板塊下挫,金圓股份(000546.CN)跌6.17%
13:15
【異動股】貴金屬板塊下挫,湖南白銀(002716.CN)跌4.59%
13:15
【異動股】航天航空板塊拉升,廣聯航空(300900.CN)漲19.99%
13:15
【異動股】空間站概念板塊拉升,天奧電子(002935.CN)漲10.01%
12:05
量化派(02685.HK)部分行使超額配股權、穩定價格行動及穩定價格期結束
11:54
浙商銀行(02016.HK):郭定方辭任監事長
11:47
麗珠醫藥(01513.HK)萊康奇塔單抗注射液上市許可申請獲國家藥監局受理